Laquinimod eye drops before vitrectomy: safety study
Part of Eyes & vision clinical trials.
This trial tests a new eye drop called Laquinimod for people who are already scheduled for a vitrectomy. The drops are given before surgery to see if they are safe and how they spread in the eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are scheduled for a vitrectomy (eye surgery to remove the gel inside the eye).
- The pressure in your study eye is between 5 and 22 mmHg (a normal range).
- If you are a woman, you are not pregnant or breastfeeding, and are either post-menopausal or have had a sterilization procedure.
- You do not have an active eye infection, and have not had recent eye surgery, steroid injections, or certain medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a small steroid implant placed inside the eye (YUTIQ 0.18 mg) can control chronic non-infectious uveitis. It may help reduce active inflammation and prevent flare-ups, as long as you’ve had recent signs of active disease and can follow the medication and eye-visit rules.
This study tests a new eye drop or solution (IRX-101) to see if it is safe and tolerable when given before or after your regular eye injections for conditions like wet macular degeneration. The goal is to find a way to make these injections more comfortable or safer.
This study tests a new anti-inflammatory eye drop (PRO-232) in people who had routine cataract surgery on one eye the day before. The goal is to see if it helps control swelling and pain without problems.
This study compares how different types of glaucoma surgery affect your daily life and well-being. If you need glaucoma surgery, you may join to help doctors understand which procedure works best from a patient's perspective.
This trial tests a new eye drop (tacrolimus) to treat non-infectious anterior uveitis, an inflammation in the front part of the eye. It may help reduce the need for steroid eye drops.
This trial tests infliximab—given as eye drops—after a first corneal transplant to see if it can improve healing and eye outcomes. It may help people at risk of inflammation after surgery, but it also requires careful screening for infection and medication safety.
Hear when a new Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.